Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490534 | 1.00 | TYMP (0.51) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL25379844 | 1.00 | TYMP (0.51) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL29881756 | 1.00 | TYMP (0.51) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL18490579 | 0.97 | TYMP (0.48) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL20474391 | 0.96 | TYMP (0.52) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL20481628 | 0.96 | TYMP (0.52) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL18048082 | 0.95 | TYMP (0.51) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL30524667 | 0.95 | TYMP (0.51) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL20474384 | 0.93 | TYMP (0.49) | TYMPTAS1R3TAS1R1NT5EKDM4E | |
| SCHEMBL18490429 | 0.93 | TYMP (0.49) | TYMPTAS1R3TAS1R1NT5EKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-07-04 | — | — | US | disclosed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11883420-B2 | Sting agonists for treating bladder cancer and solid tumors | Venenum Biodesign, LLC (US) | 2024-01-30 | — | — | US | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210290645-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | Venenum Biodesign, LLC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11110106-B2 | Sting agonists for treating bladder cancer and solid tumors | Venenum Biodesign, LLC (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210060041-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | Venenum Biodesign, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | TYMP 208/4885TAS1R3 165/4885TAS1R1 171/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | TYMP 2973/4885TAS1R3 201/4885TAS1R1 124/4885 |
| US-20210290645-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | STING1, CGAS, TBK1 | TYMP 557/4885TAS1R3 294/4885TAS1R1 199/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | TYMP 3035/4885TAS1R3 212/4885TAS1R1 134/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 2186/4885TAS1R3 560/4885TAS1R1 184/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-11883420-B2 | Sting agonists for treating bladder cancer and solid tumors | STING1, CGAS, TBK1 | TYMP 557/4885TAS1R3 294/4885TAS1R1 199/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20210060041-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | STING1, CGAS, TBK1 | TYMP 557/4885TAS1R3 294/4885TAS1R1 199/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | TYMP 1508/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-11110106-B2 | Sting agonists for treating bladder cancer and solid tumors | STING1, CGAS, TBK1 | TYMP 557/4885TAS1R3 294/4885TAS1R1 199/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | TYMP 2997/4885TAS1R3 194/4885TAS1R1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.